Cipla Q2 consolidated net profit declines by 15.64 percent

Mumbai: Pharma major, Cipla Ltd has posted a decline of 15. 64 per cent in its consolidated net profit for the quarter ended September 30, 2018, at Rs 366.91 crores as against Rs 434. 95 crores for the period ended September 30, 2017.

However, total income for the quarter under review was marginally up by 1.

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.